Is tremelimumab an immunosuppressant?

Tremelimumab (tremelimumab) is an immune checkpoint inhibitor, not an immunosuppressant. As an immune checkpoint inhibitor, temtumumab relieves the inhibition of T cell activity by inhibiting CTLA-4 protein and enhances the immune system's ability to attack tumor cells. It helps restore T-cell immune responses, thereby enhancing the rejection of cancer cells. Unlike immunosuppressants, immune checkpoint inhibitors do not directly inhibit the function of the immune system, but reverse or reduce the resistance of tumor cells to T cell immune responses.

Temimumab works by activatingT cells and enhancing the immune response of the immune system. By blocking the CTLA-4 signaling pathway, it promotes the activation, proliferation and release of immune active substances, such as interferon gamma (IFN-γ), tumor necrosis factor-α (TNF-α), etc., of T cells, further activating immune cells. The main target of temsitumumab is malignant tumors. It inhibits the growth and spread of tumors by enhancing the immune system's recognition and attack of tumor cells. Texitumumab can increase the infiltration and activity of T cells in the tumor microenvironment, increase tumor antigen presentation and killing effect, and promote the apoptosis of tumor cells.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.